west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "黄颂敏" 9 results
  • 糖尿病肾病与炎症致病作用及治疗研究进展

    糖尿病肾病(diabetic nephropathy,DN)是糖尿病的重要微血管病变之一,其发病虽与高血糖明确相关,但仍有研究显示严格控制血糖以及应用血管紧张素转换酶抑制剂或血管紧张素Ⅱ受体拮抗剂等药物仅能部分延缓DN进展,绝大部分患者最终缓慢进展至终末期肾衰竭,新的发病机制亟待探索。最近研究揭示炎症机制是DN发生发展的关键因素,本文就DN与炎症发病机制,致病作用及治疗的研究进展作相关阐述。

    Release date:2016-09-08 09:49 Export PDF Favorites Scan
  • Effects of Tripterygium on Diabetic Nephropathy: A Systematic Review

    Objective To evaluate the efficacy and safety of tripterygium for diabetic nephropathy. Methods All randomized or quasi-randomized controlled trials (RCTs or quasi-RCTs) of tripterygium for biabetic nephropathy were collected from The Cochrane Library (Issue 1, 2010), MEDLINE (1996 to March 2010), CNKI (1994 to March 2010), and CBM (1978 to March 2010). Two reviewers evaluated the quality of the trials and extracted the data independently. RevMan 5.0 software was used for meta-analyses. Results A total of 12 RCTs involving 862 patients were identified. The methodology of the included trials was poor and potential publication bias existed. The meta-analyses results showed: (1) Compared with the conventional treatment, the tripterygium showed more effects in reducing the 24-hour urinary protein (Clinical phase: WMD= –0.49, 95%CI –0.63 to –0.34, No phase: WMD= –0.60, 95%CI –0.96 to –0.24), and the urinary albumin excretion rate (UAER) (WMD= –148.75, 95%CI –238.01 to –59.48) was higher than that of the conventional treatment. (2) There were no significant differences between the two groups in the effect on the serum creatinine (Clinical phase: WMD= –8.43, 95%CI –18.15 to 1.29, No phase: WMD= –0.66, 95%CI –2.12 to 0.79) and creatinine clearance rate (WMD= 1.74, 95%CI –6.34 to 9.83). (3) Without enough data, it was uncertain to define the effect of tripterygium on lipids, blood pressure of the DN patients. (4) No severe adverse events or allergic reactions were reported. Conclusion Tripterygium may be a kind of medicine relatively safe and effective for diabetic nephropathy. However, the evidence is not b enough because of some low-quality trials and publication bias. Rigorously-designed, randomized, double-blind, and placebo-controlled trials of tripterygium for diabetic nephropathy are needed to further assess the effect.

    Release date:2016-09-07 11:23 Export PDF Favorites Scan
  • Evidence for Anaphylaxis Induced by Intramuscular Injection of Vitamin K1

    Although anaphylaxis induced by vitamin K1 seldom happens, 4 allergic cases were observed in the patients we treated recently who were given intramuscular injection of vitamin K1 before renal biopsy. To provide the best clinical evidence, we searched MEDLINE (-May 2005) and evaluated the studies. The studies were only case reports and retrospective reviews which showed the anaphylaxis were mainly allergic dermatitis with different manifestation and reaction time. The serious reactions such as allergic shock was very rare. We conclude that although vitamin K1 anaphylaxis is rare, strict indications should be followed and the drug surveillance on adverse events should be strengthened.

    Release date:2016-09-07 02:26 Export PDF Favorites Scan
  • 糖尿病肾病合并急性脊髓炎一例

    Release date:2016-09-07 02:38 Export PDF Favorites Scan
  • A Randomized Controlled Trial of Reduced Glutathione in the Treatment of Acute Renal Failure

    Objective To evaluate the effectiveness and safety of reduced glutathione in the treatment of acute renal failure. Methods Twenty-three patients with acute renal failure were divided into the treatment group (n=10) and the control group (n=13) by simple randomisation. Patients in the treatment group received intravenous reduced glutathione 1200 mg daily. Patients in the control group were not treated with reduced glutathione. The therapeutic course for both groups was 4 weeks. Serum creatinine and urea nitrogen were determined before treatment as well as at the end of each of the 4 weeks. Proximal and distal renal tubular functions were evaluated at the end of the treatment. The time when clinical symptoms were improved was recorded and adverse drug reactions were monitored. Results The durations of nausea and vomiting as well as the oliguria stage were shorter in the treatment group than in the control group. The serum creatinine level in the treatment group decreased more markedly than that in the control group. At the end of the treatment, the renal tubular function was better in the treatment group than in the control group. Conclusion Reduced glutathione contributes to the early recovery of renal function in patients with acute renal failure. However, more high-quality and large-scale randomized controlled trials are needed.

    Release date:2016-09-07 02:15 Export PDF Favorites Scan
  • Mycophenolate Mofetil for Proliferative Lupus Nephritis: A Systematic Review

    Objective To assess the effectiveness and safety of mycophenolate mofetil (MMF) in the treatment of proliferative lupus nephritis. Methods We searched CBM (November 1979 to February 2006), Chinese Cochrane Centre Database (2005), The Cochrane Library (Issue 4, 2005), MEDLINE (November 1966 to February 2006) and EMBASE (1975 to February 2006) for randomize controlled trials. Data were extracted and analyzed using The Cochrane Collaboration’s RevMan 4.2.7. Results Nine randomize controlled trials involving 512 patients met the inclusion criteria. The meta-analysis showed that the total clinical effective rate and complete remission rate were not significantly higher for MMF than for cyclophosphamide, azathioprine, or both. Renal survival rate and relapse rate of MMF were not significantly different from those for cyclophosphamide, azathioprine, or both. Patient survival rate and safety of MMF were significantly improved compared with cyclophosphamide, azathioprine, or both. Conclusion More large-scale multi-center randomized trials are needed to investigate the role of MMF in the treatment of proliferative lupus nephritis.

    Release date:2016-09-07 02:17 Export PDF Favorites Scan
  • 慢性肾功能不全合并铁粒幼细胞性贫血一例

    Release date:2016-09-08 09:26 Export PDF Favorites Scan
  • ANCA相关血管炎合并类风湿关节炎1例

    Release date:2016-09-08 10:00 Export PDF Favorites Scan
  • 高原红细胞增多症所致局灶节段性肾小球硬化一例

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content